Patent Pool Partners With Mylan And Hetero On Dolutegravir
Companies Have Deal To Supply In Azerbaijan, Belarus, Kazakhstan And Malaysia
Viatris’ Mylan and Hetero Drugs have agreed to partner with the Medicines Patent Pool to supply dolutegravir in Azerbaijan, Belarus, Kazakhstan and Malaysia.
You may also be interested in...
The Medicines Patent Pool is giving interested parties until 18 December to submit license applications for the HIV treatment dolutegravir in four middle-income countries, following announcement of the agreement last month.
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.